Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 3 study of tafasitamab plus lenalidomide with R-CHOP vs R-CHOP in DLBCL

A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma

Disease Types: Lymphoma

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

A Phase III, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma

For more information:

https://clinicaltrials.gov/ct2/show/NCT04824092?term=tafasitamab&cond=Diffuse+Large+B+Cell+Lymphoma&draw=2&rank=3